WO1996039536A1 - PROCEDE CHIMIQUE UNIVERSEL DE QUANTIFICATION DE L'EXPRESSION DE L'ARNm UTILISANT UN DOSAGE IMMUNOENZYMATIQUE - Google Patents
PROCEDE CHIMIQUE UNIVERSEL DE QUANTIFICATION DE L'EXPRESSION DE L'ARNm UTILISANT UN DOSAGE IMMUNOENZYMATIQUE Download PDFInfo
- Publication number
- WO1996039536A1 WO1996039536A1 PCT/US1996/008142 US9608142W WO9639536A1 WO 1996039536 A1 WO1996039536 A1 WO 1996039536A1 US 9608142 W US9608142 W US 9608142W WO 9639536 A1 WO9639536 A1 WO 9639536A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probe
- pcr product
- primer
- mrna
- microtiter plate
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 51
- 238000001514 detection method Methods 0.000 title description 15
- 238000002965 ELISA Methods 0.000 title description 8
- 239000000523 sample Substances 0.000 claims abstract description 62
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000002299 complementary DNA Substances 0.000 claims abstract description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 19
- 239000012472 biological sample Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000002773 nucleotide Substances 0.000 claims abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 9
- 238000002372 labelling Methods 0.000 claims abstract description 8
- 102100034343 Integrase Human genes 0.000 claims abstract description 7
- 230000009089 cytolysis Effects 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 9
- 108010006785 Taq Polymerase Proteins 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 description 51
- 239000000047 product Substances 0.000 description 31
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000012340 reverse transcriptase PCR Methods 0.000 description 9
- 239000008188 pellet Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 5
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101150003530 Tsnax gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000004986 phenylenediamines Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- an assay for the detection of mRNA expression of a selected protein in a biological sample using a universal enzyme-linked immunosorbent assay (ELISA) of probed polymerase chain reaction (PCR) products resulting from reverse transcriptase-PCR (RT-PCR) of the mRNA of interest.
- biological sample it is meant to include, but is not limited to, whole blood, serum, plasma, urine, synovial fluid, saliva, cerebrospinal fluid, tissue infiltrate, cervical or vaginal exudate, pleural effusion, bronchioalveolar lavage fluid, gastric lavage fluid, small or large bowel contents, and swab specimens from various bodily orifices dispersed in a suitable medium.
- the mixture of hybridized probe and PCR product, unhybridized probe and PCR products and excess primers are then added to a microtiter plate coated with an agent capable of binding to the molecule on either the PCR product or the probe.
- the microtiter plate is coated with streptavidin.
- a detectably labeled antibody capable of binding to any labeled PCR product which is hybridized to the probe and bound to the plate is then added and the antibody is detected.
- the antibody is detected colorimetrically or fluorometrically.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un système permettant une quantification des niveaux d'expression d'ARNm dans un échantillon biologique contenant un mélange lysant d'un détergent et d'un chaotrope pour extraire l'ARN total de l'échantillon biologique; un mélange de transcriptase inverse, de nucléotides et d'une amorce oligo-dT pour synthétiser l'ADNc à partir de l'ARNm polyadénylé dans l'ARNm total ; un moyen pour marquer une amorce ou une sonde avec une molécule qui se fixe à un agent appliqué en film sur une plaque de microtitrage; une plaque de microtitrage portant un film d'un agent capable de se fixer à ladite molécule; un moyen pour marquer une amorce ou une sonde avec un marqueur détectable; un anticorps qui détecte l'amorce ou la sonde marquée; et un moyen pour détecter l'anticorps. L'invention concerne également des méthodes de quantification de l'expression de l'ARNm dans un échantillon biologique.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU58851/96A AU5885196A (en) | 1995-06-06 | 1996-05-31 | Universal chemistry enzyme-linked immunosorbent assay for de tection of mrna expression |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46790995A | 1995-06-06 | 1995-06-06 | |
| US08/467,909 | 1995-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996039536A1 true WO1996039536A1 (fr) | 1996-12-12 |
Family
ID=23857641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/008142 WO1996039536A1 (fr) | 1995-06-06 | 1996-05-31 | PROCEDE CHIMIQUE UNIVERSEL DE QUANTIFICATION DE L'EXPRESSION DE L'ARNm UTILISANT UN DOSAGE IMMUNOENZYMATIQUE |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5885196A (fr) |
| WO (1) | WO1996039536A1 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| FR2874026A1 (fr) * | 2004-08-04 | 2006-02-10 | Centre Nat Rech Scient | QUANTIFICATION DES ARNm DE PROTEINES D'INTERET AU MOYEN D'UNE REACTION RT-PCR EN TEMPS REEL |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| WO2010012464A1 (fr) * | 2008-08-01 | 2010-02-04 | Roche Diagnostics Gmbh | Lyse et transcription inverse améliorées pour la quantification d'arnm |
| US7972778B2 (en) | 1997-04-17 | 2011-07-05 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
-
1996
- 1996-05-31 WO PCT/US1996/008142 patent/WO1996039536A1/fr active Application Filing
- 1996-05-31 AU AU58851/96A patent/AU5885196A/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| ANALYTICAL BIOCHEMISTRY, 1988, Volume 169, MATTHEWS et al., "Review, Analytical Strategies for Use of DNA Probes", pages 1-25. * |
| MANIATIS et al., "Molecular Cloning, A Laboratory Manual", NEW YORK: COLD SPRING HARBOR LABORATORY, 1982, pages 212-216 and 280-281. * |
| NUCLEIC ACIDS RESEARCH, 1986, Volume 14, Number 12, SYVANEN et al., "Fast Quantification of Nucleic Acid Hybrids by Affinity-Based Hybrid Collection", pages 5037-5048. * |
| NUCLEIC ACIDS RESEARCH, 1988, Volume 16, Number 23, SYVANEN et al., "Quantification of Polymerase Chain Reaction Products by Affinity-Based Hybrid Collection", pages 11327-11338. * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8551698B2 (en) | 1997-04-17 | 2013-10-08 | Applied Biosystems, Llc | Method of loading sample into a microfluidic device |
| US8563275B2 (en) | 1997-04-17 | 2013-10-22 | Applied Biosystems, Llc | Method and device for detecting the presence of a single target nucleic acid in a sample |
| US9506105B2 (en) | 1997-04-17 | 2016-11-29 | Applied Biosystems, Llc | Device and method for amplifying target nucleic acid |
| US8859204B2 (en) | 1997-04-17 | 2014-10-14 | Applied Biosystems, Llc | Method for detecting the presence of a target nucleic acid sequence in a sample |
| US8822183B2 (en) | 1997-04-17 | 2014-09-02 | Applied Biosystems, Llc | Device for amplifying target nucleic acid |
| US8067159B2 (en) | 1997-04-17 | 2011-11-29 | Applied Biosystems, Llc | Methods of detecting amplified product |
| US8278071B2 (en) | 1997-04-17 | 2012-10-02 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
| US7972778B2 (en) | 1997-04-17 | 2011-07-05 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
| US8257925B2 (en) | 1997-04-17 | 2012-09-04 | Applied Biosystems, Llc | Method for detecting the presence of a single target nucleic acid in a sample |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7579148B2 (en) | 2001-06-08 | 2009-08-25 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring autoimmune and chronic inflammatory diseases |
| US8110364B2 (en) | 2001-06-08 | 2012-02-07 | Xdx, Inc. | Methods and compositions for diagnosing or monitoring autoimmune and chronic inflammatory diseases |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7604936B2 (en) | 2002-04-24 | 2009-10-20 | Xdx, Inc. | Methods and compositions for diagnosis and monitoring auto immune and chronic inflammatory diseases |
| FR2874026A1 (fr) * | 2004-08-04 | 2006-02-10 | Centre Nat Rech Scient | QUANTIFICATION DES ARNm DE PROTEINES D'INTERET AU MOYEN D'UNE REACTION RT-PCR EN TEMPS REEL |
| WO2006024737A3 (fr) * | 2004-08-04 | 2006-08-31 | Centre Nat Rech Scient | QUANTIFICATION DES ARNm DE PROTEINES D'INTERET AU MOYEN D'UNE REACTION RT-PCR EN TEMPS REEL |
| WO2010012464A1 (fr) * | 2008-08-01 | 2010-02-04 | Roche Diagnostics Gmbh | Lyse et transcription inverse améliorées pour la quantification d'arnm |
| US8623602B2 (en) | 2008-08-01 | 2014-01-07 | Roche Diagnostics Operations, Inc. | Lysis and reverse transcription for MRNA quantification |
| US9714448B2 (en) | 2008-08-01 | 2017-07-25 | Roche Molecular Systems, Inc. | Lysis and reverse transcription for MRNA quantification |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5885196A (en) | 1996-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10407723B2 (en) | Methods and compositions for nucleic acid amplification | |
| AU624601B2 (en) | Amplification and detection of nucleic acid sequences | |
| JP4975905B2 (ja) | 複合生物試料における核酸の単工程調製及び検出 | |
| JPH0669374B2 (ja) | ランダム配列オリゴヌクレオチドをプライマーとする核酸配列の増幅 | |
| JP5656273B2 (ja) | 試験サンプルにおいてｔｒｉｃｈｏｍｏｎａｓｖａｇｉｎａｌｉｓの存在を決定するための組成物、方法およびキット | |
| CA2658105A1 (fr) | Procedes de capture de cible non specifique d'acides nucleiques | |
| JP2005511030A (ja) | 核酸の増幅方法 | |
| JPH06209799A (ja) | 鳥型結核菌、ミコバクテリウム・イントラセルレアおよびパラ結核菌に対するプローブ | |
| US6027886A (en) | Method for the quantitative detection of specific nucleic acid sequences | |
| WO1996039536A1 (fr) | PROCEDE CHIMIQUE UNIVERSEL DE QUANTIFICATION DE L'EXPRESSION DE L'ARNm UTILISANT UN DOSAGE IMMUNOENZYMATIQUE | |
| EP1275738A1 (fr) | Procédé pour la synthèse aléatoire et l'amplification d'ADNc | |
| JP2003516764A (ja) | マイコバクテリウム属（Ｍｙｃｏｂａｃｔｅｒｉｕｍ）種の核酸増幅および検出 | |
| US9121054B2 (en) | Detection of nucleic acid amplification products in the presence of an internal control sequence on an immunochromatographic strip | |
| US6747141B2 (en) | Methods and compositions for detection of mycobacterium avium complex species | |
| EP1275734A1 (fr) | Méthode pour la synthèse aléatoire et l'amplification d'ADNc | |
| US5955271A (en) | Method and kits for determining messenger RNA molecules in a sample | |
| JPH06209776A (ja) | 単純な核酸増幅方法 | |
| Richards | Gene probes | |
| JP2003519466A (ja) | テロメラーゼ（ｈＴＣ）ｍＲＮＡおよび特異的プライマーおよびプローブに基づいたガンを検出するための自動化可能な迅速な試験 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR CA CN CZ EE FI GE HU IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |